55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules

Primary Hypothyroidism: Etiology, Clinical Manifestations & Pharmacotherapy

Hypothyroidism is a common clinical disorder characterized by systemic deficiency of thyroid hormones, leading to generalized hypometabolism. Primary hypothyroidism accounts for >95% of cases and results from direct intrinsic thyroid gland failure, reflected biochemically by an elevated serum thyroid-stimulating hormone (TSH) and a low serum free thyroxine (free T4).

Etiologies of Primary Hypothyroidism

• Hashimoto Thyroiditis (Chronic Autoimmune Thyroiditis):
  • The most common cause of hypothyroidism in iodine-sufficient geographic areas (including North America).
  • Autoimmune destruction mediated by CD4+ and CD8+ T-lymphocytes and autoantibodies targeting thyroid tissue: anti-thyroperoxidase (anti-TPO) antibodies (present in 90% to 95% of patients) and anti-thyroglobulin (anti-Tg) antibodies (present in 60% to 80%).
  • Histopathology demonstrates extensive lymphocytic infiltration, germinal centers, destruction of thyroid follicles, and characteristic metaplastic Hurthle (Askanazy) cells with prominent eosinophilic granular cytoplasm.
  • Carries a markedly increased long-term risk of primary thyroid lymphoma (typically non-Hodgkin B-cell lymphoma), which should be suspected if a patient with longstanding Hashimoto disease develops a rapidly enlarging, firm neck mass.
• Iatrogenic & Post-Ablative:
  • Radioactive iodine ($^{131}\text{I}$) therapy for Graves disease or toxic goiter (predictable development of permanent hypothyroidism within 3 to 12 months).
  • Total or subtotal surgical thyroidectomy.
  • External beam neck irradiation for Hodgkin lymphoma or head and neck malignancies.
• Iodine Deficiency & Iodine Excess:
  • Iodine Deficiency: The most common cause of hypothyroidism and endemic goiter worldwide.
  • Iodine Excess (The Wolff-Chaikoff Effect): High intrathyroidal concentrations of inorganic iodide paradoxically inhibit thyroid peroxidase and organification of iodide. In healthy individuals, the gland "escapes" from this inhibition within several days; however, in patients with underlying autoimmune thyroiditis, the escape mechanism fails, leading to persistent iodine-induced hypothyroidism. Common sources include amiodarone (each 200 mg tablet contains 75 mg of iodine, releasing 7 mg of free inorganic iodine daily) and iodinated intravenous radiocontrast media.
• Pharmacologic Inhibitors:
  • Lithium: Accumulates in the thyroid gland, inhibiting thyroid hormone synthesis and release (hypothyroidism develops in 15% to 20% of chronic users).
  • Immune Checkpoint Inhibitors (anti-PD-1 [pembrolizumab, nivolumab], anti-CTLA-4 [ipilimumab]): Induce destructive autoimmune thyroiditis, often presenting with a brief transient thyrotoxic phase followed by permanent primary hypothyroidism.
  • Tyrosine Kinase Inhibitors (sunitinib, sorafenib): Cause thyroid capillary regression and ischemic follicular atrophy.

Clinical Manifestations

Because thyroid hormones regulate cellular metabolic rate throughout all tissues, clinical features reflect generalized slowing of organ systems:

                     CLINICAL MANIFESTATIONS OF HYPOTHYROIDISM

   System                 Signs and Symptoms
   ═════════════════════════════════════════════════════════════════════════════
   Constitutional         Fatigue, lethargy, cold intolerance, unexplained modest weight gain
                          (typically 5-10 lbs, predominantly fluid retention), hypothermia

   Dermatologic           Dry, coarse, scaly skin; brittle hair and nails; diffuse alopecia;
                          loss of outer third of the eyebrows (madarosis); non-pitting
                          myxedematous puffiness (periorbital and pretibial glycosaminoglycan deposition)

   Neuromuscular          Delayed relaxation phase of deep tendon reflexes ("hung-up" reflex,
                          Woltman sign, most easily recognized at Achilles tendon);
                          proximal muscle weakness, myalgias, carpal tunnel syndrome

   Gastrointestinal       Severe constipation, decreased peristalsis, paralytic ileus

   Cardiovascular         Bradycardia, narrowed pulse pressure, diastolic hypertension,
                          pericardial effusion, decreased cardiac contractility

   Reproductive / Endo    Menorrhagia, oligomenorrhea, anovulation, infertility;
                          hyperprolactinemia and galactorrhea (compensatory high TRH directly
                          stimulates pituitary lactotrophs to secrete prolactin)

   Metabolic / Labs       Hyponatremia (impaired free water clearance secondary to elevated ADH),
                          normocytic or macrocytic anemia, elevated LDL-cholesterol, elevated CK
   ═════════════════════════════════════════════════════════════════════════════

Levothyroxine Pharmacotherapy & Administration Counseling

Synthetic levothyroxine ($T_4$) is the sole first-line replacement therapy of choice. Triiodothyronine ($T_3$, liothyronine) and desiccated thyroid extract (Armour Thyroid) are not recommended for routine initial therapy due to short half-lives, fluctuating plasma concentrations, supraphysiologic $T_3$ spikes, and heightened cardiovascular risk.

                    LEVOTHYROXINE INITIAL DOSING STRATIFICATION

   Patient Population                    Recommended Initial Levothyroxine Dosing Strategy
   ═════════════════════════════════════════════════════════════════════════════════════════════════
   Young (< 50-60 years), Healthy,      Full weight-based replacement: ~1.6 mcg/kg/day
   No Coronary Disease                  (calculated using ideal body weight; typically 75-125 mcg/day)

   Older Adults (>= 50-60 years)        Conservative starting dose: 25 to 50 mcg/day;
   WITHOUT Known CAD                    titrate upward by 12.5 to 25 mcg increments every 6 to 8 weeks

   Documented Coronary Artery Disease   "Start low and go slow": 12.5 to 25 mcg/day;
   or Severe Frailty / Heart Failure    titrate by 12.5 mcg every 6 to 8 weeks under close clinical monitoring
   ═════════════════════════════════════════════════════════════════════════════════════════════════
   *Rationale for Elderly/CAD Caution: Full replacement abruptly increases myocardial oxygen demand (MVO2),
   which can precipitate severe angina, acute myocardial infarction, or fatal tachyarrhythmias.

• Crucial Patient Administration Counseling:

  • Empty Stomach Requirement: Levothyroxine absorption occurs primarily in the duodenum and jejunum, requiring gastric acidity for optimal dissolution (oral bioavailability 60% to 80%). The tablet must be taken with a full glass of plain water at least 30 to 60 minutes before breakfast, or alternatively at bedtime at least 3 to 4 hours after the final evening meal.
  • The 4-Hour Separation Rule: Levothyroxine binds avidly to polyvalent cations and compounds that alter gastric pH. Patients must separate levothyroxine ingestion by at least 4 hours from:
    • Calcium carbonate and calcium citrate supplements
    • Ferrous sulfate and iron-containing multivitamins
    • Aluminum- or magnesium-containing antacids and sucralfate
    • Proton pump inhibitors (omeprazole, pantoprazole) and H2-receptor antagonists
    • Bile acid sequestrants (cholestyramine, colesevelam)
    • Dietary espresso/coffee, soy products, and high-fiber foods

• Therapeutic Monitoring Protocol:

  • Synthetic $T_4$ possesses an elimination half-life of 7 days, requiring approximately 6 weeks (5 half-lives) to reach steady-state serum concentrations.
  • Measure serum TSH 6 to 8 weeks after initiating therapy or after any dosage adjustment.
  • Once the target serum TSH is achieved within the normal laboratory reference range (typically 0.5 to 4.5 mIU/L), monitoring can be spaced to every 6 to 12 months, or sooner if the patient experiences significant weight changes, starts interfering medications, or becomes pregnant.

• Pregnancy Considerations & Dosing Protocol:

  • Thyroid hormone is indispensable for early fetal neurodevelopment. Prior to 10 to 12 weeks gestation, the fetus is entirely dependent on transplacental transfer of maternal $T_4$.
  • Estrogen surges during early pregnancy double circulating thyroxine-binding globulin (TBG), and human chorionic gonadotropin (hCG) weakly stimulates the TSH receptor, leading to a mandatory 25% to 50% increase in maternal thyroid hormone requirements.
  • Pre-Conception Counseling: Women on levothyroxine contemplating pregnancy should optimize preconception TSH to < 2.5 mIU/L.
  • Immediate Pregnancy Dose Escalation: As soon as pregnancy is confirmed (e.g., positive home pregnancy test), the patient should immediately increase her levothyroxine dose by approximately 25% to 30% without waiting for laboratory confirmation. A standard practical instruction is to take two additional tablets per week (e.g., taking a double dose on two non-consecutive days, such as Monday and Friday).
  • Trimester Monitoring: Recheck serum TSH every 4 weeks throughout the first half of pregnancy (up to 20 weeks gestation), and at least once between 26 and 32 weeks. The target TSH during pregnancy is <2.5 mIU/L (or within lower trimester-specific reference ranges). Following delivery, maternal levothyroxine is immediately reduced to the patient's pre-pregnancy baseline dose, with TSH checked at 6 weeks postpartum.

Subclinical Hypothyroidism: Diagnosis & Evidence-Based Treatment Indications

Subclinical hypothyroidism is a biochemical diagnosis defined by an elevated serum TSH level in the presence of a normal serum free T4 level. It is prevalent in 4% to 10% of the general adult population, with higher rates observed in older women.

                  BIOCHEMICAL SPECTRUM OF THYROID FUNCTION TESTS

   Clinical State                   Serum TSH Level          Serum Free T4 Level
   ═════════════════════════════════════════════════════════════════════════════
   Overt Primary Hypothyroidism     Elevated (> 4.5 mIU/L)   Low (< normal range)
   Subclinical Hypothyroidism       Elevated (> 4.5 mIU/L)   Normal (within range)
   Euthyroid Baseline               Normal (0.5 - 4.5 mIU/L) Normal (within range)
   Subclinical Hyperthyroidism      Suppressed (< 0.4 mIU/L) Normal (within range)
   Overt Hyperthyroidism            Suppressed (< 0.1 mIU/L) Elevated (> normal range)
   ═════════════════════════════════════════════════════════════════════════════

Clinical Rule: Confirm Before Treating

A single mildly elevated TSH reading must never trigger automatic lifelong pharmacotherapy. Up to 30% to 50% of mildly elevated TSH values spontaneously normalize on repeat testing. Transient elevations frequently occur during recovery from non-thyroidal illness (euthyroid sick syndrome) or following viral destructive thyroiditis. Clinicians must re-evaluate serum TSH and free T4 in 6 to 12 weeks before establishing the diagnosis of persistent subclinical hypothyroidism.

Indications for Levothyroxine Treatment in Subclinical Hypothyroidism

Initiating levothyroxine in subclinical hypothyroidism remains nuanced. The decision is driven by the absolute degree of TSH elevation, cardiovascular risk factors, reproductive plans, and symptoms:

1. Marked Elevation: Serum TSH >= 10.0 mIU/L:
   • Definitive Treatment Indication: Guidelines from the American Thyroid Association (ATA) and American Association of Clinical Endocrinology (AACE) universally recommend levothyroxine replacement for all patients with confirmed TSH >=10.0 mIU/L, regardless of symptoms.
   • Clinical Rationale: A TSH >=10.0 mIU/L is associated with a significantly increased risk of adverse cardiovascular outcomes, including accelerated atherosclerosis, ischemic heart disease events, diastolic dysfunction, and a 40% to 50% higher risk of heart failure hospitalization. In addition, the annual rate of progression from subclinical to overt hypothyroidism exceeds 5% per year in this cohort.
2. Pregnancy or Active Infertility Workup:
   • Definitive Treatment Indication: Any pregnant woman with subclinical hypothyroidism (TSH >2.5 mIU/L with normal free T4) or any woman undergoing assisted reproductive technology (ART) must be treated with levothyroxine to reduce risks of spontaneous abortion, preeclampsia, placental abruption, and adverse fetal neurocognitive development.
3. Mild Elevation: Serum TSH > Upper Limit of Normal to 9.9 mIU/L:
   • Treatment is selective and individualized based on the following specific clinical criteria:
     • Severe or Classic Hypothyroid Symptoms: A therapeutic trial of low-dose levothyroxine (25 to 50 mcg/day) for 3 to 6 months is reasonable; if symptoms do not objectively improve, the medication should be discontinued.
     • Presence of Goiter: To prevent further thyromegaly.
     • Positive Anti-Thyroperoxidase (Anti-TPO) Antibodies: Indicates underlying Hashimoto thyroiditis, conferring a high annual rate of progression to overt disease (~4.3% per year vs. 2.6% in antibody-negative patients).
     • Younger Age (< 65-70 years) with high cardiovascular risk profiles or hyperlipidemia.
4. The Elderly Paradox (Patients Aged >= 65-70 Years):
   • In older adults, serum TSH physiologically shifts upward with aging. Landmark randomized controlled trials (such as the TRUST trial) demonstrated that levothyroxine treatment for subclinical hypothyroidism in adults aged 65 years and older provided no symptomatic benefit, no improvement in cognitive function, and no reduction in fatigue or cardiovascular events.
   • Furthermore, treatment in this demographic introduces substantial risks of iatrogenic thyrotoxicosis, precipitating atrial fibrillation, osteoporosis, and fragility fractures.
   • Recommendation: For patients aged >=65 to 70 years with mild subclinical hypothyroidism (TSH < 10.0 mIU/L), routine levothyroxine therapy is NOT recommended; watchful waiting with serial thyroid function tests every 6 to 12 months is the standard of care.

Thyrotoxicosis & Hyperthyroidism: Differential Diagnosis & Evidence-Based Management

Thyrotoxicosis describes the clinical hypermetabolic syndrome resulting from inappropriately high circulating concentrations of free thyroid hormones ($T_4$ and/or $T_3$). Hyperthyroidism is a subset of thyrotoxicosis caused specifically by de novo excess thyroid hormone synthesis by the thyroid gland itself.

Diagnostic Differentiation of Thyrotoxicosis

Biochemical screening begins with serum TSH, which is suppressed (<0.01-0.1 mIU/L), accompanied by elevated free T4 and/or free T3. The definitive diagnostic tool to differentiate etiologies is the 24-Hour Radioactive Iodine Uptake and Scan (RAIU):

                  DIAGNOSTIC DIFFERENTIATION OF THYROTOXICOSIS

   Condition               Pathophysiology              Exam Findings             RAIU Pattern / Labs
   ═════════════════════════════════════════════════════════════════════════════════════════════════════
   Graves Disease          Autoimmune TSI / TRAb        Diffuse, non-tender       Diffuse, homogeneous,
                           stimulates TSH receptors     goiter with bruit;        elevated uptake (50-80%);
                                                        proptosis; pretibial      positive TSI / TRAb
                                                        myxedema (dermopathy)

   Toxic Multinodular      Autonomous hyperfunctioning  Large, asymmetric,        Patchy, heterogeneous
   Goiter (Plummer)        follicles (older adults)     nodular goiter; no        uptake with areas of hot
                                                        eye/skin signs            and suppressed tissue

   Toxic Adenoma           Single autonomous somatic    Solitary palpable nodule; Focal hot nodule with
                           TSH receptor mutation        remainder normal          complete suppression of
                                                                                  the rest of the gland

   Subacute (De Quervain)  Post-viral inflammatory      Exquisitely tender,       Low / near-zero RAIU (<1%);
   Thyroiditis             follicular disruption        painful goiter radiating  markedly elevated ESR/CRP;
                           releasing stored hormone     to jaw; fever, malaise    low thyroglobulin

   Subacute Lymphocytic    Autoimmune destruction       Painless, non-tender,     Low / near-zero RAIU (<1%);
   (Silent / Postpartum)   (within 1 yr of delivery)    normal or firm goiter     positive anti-TPO (50-80%)

   Factitious              Exogenous thyroid hormone    Thyroid gland is small,   Low / near-zero RAIU (<1%);
   Thyrotoxicosis          ingestion (surreptitious)    non-palpable, or atrophic low serum thyroglobulin
   ═════════════════════════════════════════════════════════════════════════════════════════════════════

Management Modalities for Graves Disease

Graves disease is the most common cause of hyperthyroidism (60% to 80% of cases), characterized by autoantibodies against the TSH receptor (thyroid-stimulating immunoglobulins, TSI). Three definitive therapeutic options exist, paired with initial symptomatic control:

1. Symptomatic Adrenergic Blockade (Beta-Blockers):
   • Propranolol (20 to 40 mg PO three to four times daily) or Atenolol (25 to 50 mg daily) should be initiated immediately in all symptomatic patients with moderate-to-severe thyrotoxicosis to control palpitations, tachycardia, tremors, and heat intolerance.
   • High-dose propranolol (>=160 mg/day) provides the added pharmacologic benefit of weakly inhibiting peripheral 5'-monodeiodinase conversion of $T_4$ to active $T_3$.
2. Antithyroid Drugs (Thionamides: Methimazole vs. PTU):
   • Mechanism of Action: Both agents act as competitive inhibitors of thyroid peroxidase (TPO), blocking the organification of iodide and the coupling of iodotyrosines, thereby halting de novo thyroid hormone synthesis.
   • Methimazole (MMI): The preferred first-line antithyroid drug for virtually all non-pregnant adults and children due to once-daily dosing (5 to 30 mg daily), rapid efficacy, and a substantially lower risk of fatal hepatotoxicity compared to PTU.
   • Propylthiouracil (PTU): Administered in divided doses (100 to 150 mg PO three times daily). In addition to inhibiting TPO, PTU partially inhibits peripheral conversion of $T_4$ to $T_3$.
   • Indications for PTU Over Methimazole:
     • First Trimester of Pregnancy (Weeks 1 to 12): Methimazole is a recognized teratogen associated with aplasia cutis congenita (congenital scalp defects) and choanal or esophageal atresia. PTU carries lower embryopathy risks and is the mandatory drug of choice in the first trimester. At the start of the second trimester (week 13), patients are routinely switched to methimazole to avoid PTU-induced maternal hepatotoxicity.
     • Thyroid Storm: PTU's ability to acutely block peripheral $T_4$-to-$T_3$ conversion makes it the thionamide of choice.
     • Severe Methimazole Allergy: When radioiodine or surgery is delayed.
   • Critical Adverse Effects of Thionamides:
     • Agranulocytosis (absolute neutrophil count [ANC] <500/mcL): Occurs in 0.2% to 0.5% of patients, typically within the first 90 days of therapy. Idiosyncratic, immune-mediated destruction of myeloid precursors. Mandatory Patient Warning: Educate every patient to immediately stop taking the medication and obtain a stat Complete Blood Count (CBC) with differential if they develop a fever, sore throat (pharyngitis), mouth sores, or signs of infection! Routine serial CBC monitoring without symptoms is not cost-effective.
     • Hepatotoxicity: PTU carries an FDA Black Box warning for fulminant hepatic necrosis leading to acute liver failure, transplantation, or death. Methimazole typically causes cholestatic jaundice rather than hepatocellular necrosis.
     • Minor reactions: Pruritic maculopapular rash, urticaria, arthralgias (5% of patients; managed with antihistamines without stopping therapy unless severe).
3. Radioactive Iodine ($^{131}\text{I}$) Ablation:
   • Administered orally as a single sodium iodide-131 capsule. Beta particles destroy follicular cells over 6 to 18 weeks, inducing permanent hypothyroidism in >80% to 90% of patients.
   • Absolute Contraindications: Pregnancy and breastfeeding (RAI concentrates in fetal/neonatal thyroid, causing cretinism).
   • Relative Contraindication: Moderate-to-Severe Active Graves Orbitopathy: Radioactive iodine ablation causes cell lysis, releasing large quantities of thyroid antigens into circulation, which can trigger an autoimmune flare that dramatically worsens exophthalmos and retro-orbital fibrosis. If RAI is administered to patients with mild orbitopathy, concurrent oral prednisone prophylaxis (0.3 to 0.5 mg/kg/day tapered over 3 months) is mandatory.
4. Total or Near-Total Thyroidectomy:
   • Indications: Obstructive compressive symptoms (dysphagia, stridor, retrosternal extension); coexisting suspicious or malignant thyroid nodule; moderate-to-severe active Graves ophthalmopathy; pregnancy when antithyroid medications are contraindicated or toxic; or patient preference against radioiodine.
   • Preoperative Preparation: Must achieve euthyroidism preoperatively using antithyroid drugs plus saturated solution of potassium iodide (SSKI or Lugol solution) given 7 to 10 days preoperatively to decrease thyroid gland vascularity and intraoperative hemorrhage.
   • Surgical Complications: Postoperative hypocalcemia from transient or permanent hypoparathyroidism (check ionized calcium/PTH post-op) and recurrent laryngeal nerve palsy (hoarseness).

Subacute Granulomatous (De Quervain) Thyroiditis

• Self-limiting inflammatory condition typically following a viral upper respiratory infection (Coxsackievirus, adenovirus, mumps, echovirus).
• Hallmark Features: Exquisitely painful and tender enlarged thyroid gland, with severe neck pain radiating to the jaw, ears, or occiput, accompanied by low-grade fever and malaise.
• Laboratory Profile: Markedly elevated erythrocyte sedimentation rate (ESR often >60 to 100 mm/hr) and high C-reactive protein (CRP). Thyroid hormone levels exhibit a triphasic clinical course: transient thyrotoxicosis (4-6 weeks) -> transient hypothyroidism (weeks to months) -> complete euthyroid recovery (>90% of cases).
• Treatment Protocol: Antithyroid drugs (methimazole, PTU) are completely contraindicated and ineffective because thyrotoxicosis is caused by follicular leakage of preformed colloid, not new synthesis. High-dose NSAIDs (ibuprofen 600-800 mg three times daily) are first-line for mild-to-moderate pain. For severe pain or refractory cases, initiate oral prednisone (40 mg daily tapered over 4 to 6 weeks). Beta-blockers (propranolol) manage adrenergic thyrotoxic symptoms.

Acute Thyroid Storm: The 5-Drug Resuscitation Bundle

Thyroid storm is a catastrophic, life-threatening hypermetabolic emergency characterized by decompensated multi-organ failure, carrying a mortality rate of 10% to 30%. Diagnosed clinically using the Burch-Wartofsky Point Scale (score >=45 highly suggestive).

• Clinical Hallmarks: Hyperpyrexia (fever 104°F to 106°F [40°C-41°C]), marked sinus tachycardia (>140 bpm), atrial fibrillation, congestive heart failure, profuse diaphoresis, severe agitation, delirium, frank psychosis, diarrhea, nausea, and jaundice.
• The Immediate 5-Drug Resuscitation Sequence:
  1. Step 1: Beta-Blocker: Propranolol 60 to 80 mg PO every 4 hours (or IV esmolol infusion) to block peripheral sympathetic storm and inhibit $T_4$-to-$T_3$ conversion.
  2. Step 2: Antithyroid Drug: Propylthiouracil (PTU) 500 to 1,000 mg loading dose PO/rectal, followed by 250 mg every 4 hours to halt new hormone synthesis.
  3. Step 3: Inorganic Iodine (Lugol Solution or SSKI): Administer Lugol solution (10 drops TID) or SSKI (5 drops q6h) STRICTLY AT LEAST 1 HOUR AFTER THE INITIAL PTU DOSE! Administering iodine before blocking the gland allows the thyroid to utilize the exogenous iodine as substrate for accelerated de novo hormone synthesis (the Jod-Basedow phenomenon), worsening thyrotoxicosis. When given after PTU, high-dose iodine acutely inhibits thyroid hormone release (the Wolff-Chaikoff effect).
  4. Step 4: High-Dose Glucocorticoids: Hydrocortisone 100 mg IV every 8 hours (or dexamethasone 2 mg q6h) to reduce peripheral $T_4$-to-$T_3$ conversion and protect against relative adrenal exhaustion.
  5. Step 5: Supportive Cooling & Bile Acid Sequestrants: Acetaminophen for fever (avoid aspirin / NSAIDs, which displace $T_4$ and $T_3$ from thyroxine-binding globulin, elevating free hormone levels!); active external cooling blankets; cholestyramine 4 g PO QID to bind thyroid hormones in the gut lumen and interrupt enterohepatic recirculation.

Thyroid Nodules: ATA Evaluation Guidelines, TI-RADS & Bethesda Cytopathology

Thyroid nodules are exceptionally common in clinical practice, identifiable by high-resolution ultrasonography in up to 50% to 60% of asymptomatic adults. The primary clinical imperative is excluding thyroid carcinoma, which occurs in approximately 7% to 15% of evaluated nodules.

American Thyroid Association (ATA) Stepwise Evaluation Protocol

                  ATA THYROID NODULE INITIAL DIAGNOSTIC PROTOCOL

   Palpable Thyroid Nodule OR Incidentaloma Detected on Imaging (CT, MRI, PET)
                                    │
                                    ▼
               Measure Serum TSH + Dedicated Thyroid Ultrasound
                                    │
                 ┌──────────────────┴──────────────────┐
                 ▼                                     ▼
      Serum TSH is SUPPRESSED                 Serum TSH is NORMAL or ELEVATED
                 │                                     │
                 ▼                                     ▼
     Radionuclide Thyroid Scan               Dedicated Neck Ultrasonography
     (I-123 or Tc-99m Scintigraphy)          (Stratify by ACR TI-RADS Criteria)
                 │                                     │
        ┌────────┴────────┐                            ▼
        ▼                 ▼                  Determine Need for Fine-Needle
   "HOT" Nodule      "COLD" Nodule           Aspiration (FNA) Biopsy
   (Autonomous)      (Non-functioning)       Based on TI-RADS Score & Size
        │                 │
   NO BIOPSY!        Proceed to
   Treat Hyperthy    Ultrasound-Guided
   (Surgery/RAI)     FNA per TI-RADS

• Step 1: Serum TSH Measurement:
  • If serum TSH is suppressed (< normal), the patient has hyperthyroidism or autonomous nodular function. The next mandatory diagnostic step is a radionuclide thyroid scan (using Iodine-123 or Technetium-99m).
    • Hot (Hyperfunctioning) Nodule: Accumulates radiotracer with suppression of surrounding extranodular tissue. Hot nodules are virtually never malignant (<1% cancer risk) and do NOT require fine-needle aspiration (FNA) biopsy! Manage medically or with radioiodine ablation.
    • Cold (Non-functioning) Nodule: Shows decreased or absent radiotracer uptake compared to normal parenchyma. Carries an ~8% to 15% malignancy risk; proceed to dedicated neck ultrasound and biopsy evaluation.
  • If serum TSH is normal or elevated, a radionuclide scan is completely uninformative. The patient requires a dedicated high-resolution neck ultrasound to evaluate nodule morphology and cervical lymph node stations.

ACR TI-RADS: Ultrasound Risk Stratification & Biopsy Criteria

The American College of Radiology Thyroid Imaging, Reporting and Data System (ACR TI-RADS) standardizes ultrasound risk stratification. Points are assigned across 5 ultrasound categories, generating a cumulative score that dictates whether FNA or serial surveillance is required:

                  ACR TI-RADS SCORING CATEGORIES & POINTS

   Category          Ultrasound Features & Assigned Points
   ═════════════════════════════════════════════════════════════════════════════
   Composition       Cystic or completely cystic (0 pts) | Spongiform (0 pts)
                     Mixed cystic and solid (1 pt)       | Solid or almost completely solid (2 pts)

   Echogenicity      Anechoic (0 pts)                    | Hyperechoic or isoechoic (1 pt)
                     Hypoechoic (2 pts)                  | Very hypoechoic (3 pts)

   Shape             Wider-than-tall (0 pts)             | Taller-than-wide (AP > Transverse) (3 pts)

   Margin            Smooth (0 pts)                      | Ill-defined (0 pts)
                     Lobulated or irregular (2 pts)      | Extra-thyroidal extension (3 pts)

   Echogenic Foci    None or large comet-tail artifacts (0 pts)
                     Macrocalcifications (1 pt)          | Peripheral (rim) calcifications (2 pts)
                     Punctate echogenic foci (microcalcifications) (3 pts)
   ═════════════════════════════════════════════════════════════════════════════

                  ACR TI-RADS CLASSIFICATION & FNA SIZE CUTOFFS

   TI-RADS Level   Suspicion Level        Total Points   FNA Biopsy Threshold   Follow-Up US Threshold
   ═════════════════════════════════════════════════════════════════════════════════════════════════
   TR1             Benign                 0 points       No FNA                 No follow-up
   TR2             Not Suspicious         2 points       No FNA                 No follow-up
   TR3             Mildly Suspicious      3 points       Biopsy if >= 2.5 cm    Follow if >= 1.5 cm
   TR4             Moderately Suspicious  4 to 6 points  Biopsy if >= 1.5 cm    Follow if >= 1.0 cm
   TR5             Highly Suspicious      >= 7 points    Biopsy if >= 1.0 cm    Follow if >= 0.5 cm
   ═════════════════════════════════════════════════════════════════════════════════════════════════
   *Any nodule presenting with suspicious cervical lymphadenopathy warrants immediate biopsy of the lymph node
   and thyroid nodule regardless of TI-RADS points or size.

The Bethesda System for Reporting Thyroid Cytopathology

Fine-needle aspiration (FNA) cytology is interpreted according to the internationally standardized Bethesda System, which guides oncologic risk stratification and surgical decision-making:

                  THE BETHESDA SYSTEM FOR THYROID CYTOPATHOLOGY

   Bethesda Class   Diagnostic Category                      Malignancy Risk   Clinical Management Strategy
   ═════════════════════════════════════════════════════════════════════════════════════════════════════
   Bethesda I       Nondiagnostic or Unsatisfactory          1% to 4%          Repeat ultrasound-guided FNA in
                    (insufficient follicular cells, cyst)                      6 to 12 weeks

   Bethesda II      Benign                                   0% to 3%          Clinical & ultrasound surveillance
                    (colloid nodule, lymphocytic thyroiditis)                  at 12 to 24 months; no surgery

   Bethesda III     Atypia of Undetermined Significance     10% to 30%        Molecular testing (ThyroSeq/Afirma)
                    (AUS) or Follicular Lesion (FLUS)                          OR repeat FNA in 3 months

   Bethesda IV      Follicular Neoplasm or Suspicious       25% to 40%        Molecular testing OR diagnostic
                    for Follicular Neoplasm (FN/SFN)                           surgical lobectomy (hemithyroidectomy)

   Bethesda V       Suspicious for Malignancy                60% to 75%        Surgical resection: thyroid lobectomy
                    (features concerning for papillary cancer)                 or total thyroidectomy

   Bethesda VI      Malignant                                97% to 99%        Definitive oncologic surgery:
                    (frank papillary, medullary, anaplastic)                   total thyroidectomy ± neck dissection
   ═════════════════════════════════════════════════════════════════════════════

• Pathology Nuance for Bethesda IV (Follicular Neoplasms):
  • Cytopathology from an FNA cannot distinguish a benign follicular adenoma from a malignant follicular thyroid carcinoma. The cytological appearance of follicular cells is identical in both.
  • The definitive histopathologic hallmark distinguishing follicular carcinoma is the demonstration of capsular invasion or vascular invasion through the tumor capsule, which requires full histologic sectioning of the resected surgical specimen. Therefore, surgical lobectomy or validated molecular testing is required.

Thyroid Malignancies: Clinical & Pathologic Hallmarks

1. Papillary Thyroid Carcinoma (PTC):
   • Most common thyroid malignancy (80% to 85% of all cases); 3:1 female predilection; associated with prior childhood ionizing radiation exposure.
   • Prognosis: Excellent (>95% to 98% 10-year survival rate).
   • Pathologic Hallmarks: Spreads predominantly via lymphatics to regional cervical lymph nodes. Characteristic microscopic cytological features:
     • Enlarged, overlapping, clear ground-glass nuclei ("Orphan Annie eye" nuclei)
     • Longitudinal nuclear grooves and intranuclear cytoplasmic pseudo-inclusions
     • Psammoma bodies: Concentrically laminated, basophilic calcospherites (calcified necrotic papillae tips).
2. Follicular Thyroid Carcinoma (FTC):
   • Second most common (10% to 15% of cases); more prevalent in iodine-deficient areas.
   • Spread Pattern: Spreads hematogenously (via blood vessels) to distant bones and lungs; regional lymph node involvement is rare (<10%). Excellent overall prognosis (~85% to 90% 10-year survival).
3. Medullary Thyroid Carcinoma (MTC):
   • Arises from neuroendocrine parafollicular C-cells that synthesize calcitonin (accounts for 3% to 5% of thyroid cancers).
   • Familial Association: 25% of cases are hereditary, driven by germline activating mutations in the RET proto-oncogene as a component of Multiple Endocrine Neoplasia Type 2 (MEN 2A and MEN 2B) or Familial MTC.
   • Clinical Biomarkers: Serum calcitonin (diagnostic marker and tumor burden monitor) and carcinoembryonic antigen (CEA).
   • MANDATORY BOARD EXAM RULE: Before undertaking thyroid surgery in a patient diagnosed with medullary thyroid carcinoma, the clinician must always screen for a coexisting pheochromocytoma (measure plasma free metanephrines or 24-hour urine metanephrines)! Overlooking an occult pheochromocytoma can trigger fatal intraoperative hypertensive crisis during anesthesia induction.
4. Anaplastic (Undifferentiated) Thyroid Carcinoma:
   • Accounts for 1% to 2% of thyroid cancers, occurring predominantly in elderly patients (>=65 years).
   • Clinical Presentation: Catastrophically aggressive, rapidly enlarging, rock-hard anterior neck mass that infiltrates surrounding cervical structures within weeks, presenting with acute hoarseness, stridor, dyspnea, and dysphagia.
   • Prognosis: Dreadful (median survival 3 to 6 months). Highly resistant to radioiodine, surgical cure, and conventional chemotherapy. Management focuses on securing the airway (tracheostomy) and palliative targeted therapies.